Joseph T. Rabban III, MD, MPH

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Joseph T. Rabban III, MD, MPH

Associate Professor, Department of Pathology, UCSF

joseph.rabban@ucsf.edu

Phone: (415) 353-2292 (voice)
Box 0102, UCSF
San Francisco, CA 94143-0102

View on UCSF Profiles

Cancer Center Membership

Associate Member » Breast Oncology

Research Summary

I am a diagnostic surgical pathologist with a focus on women's cancer, including gynecologic cancers (ovary, uterus, cervix, fallopian tubes, peritoneum, vagina, vulva) and breast cancers. I provide diagnostic services to the clinics and operating rooms at Moffitt Hospital and Mt Zion Cancer Center and collaborate clinically with colleagues in the Gynecologic Oncology division and Breast Care Center.

My clinical research focuses on improving predictive and prognostic understanding of gynecologic and breast cancers using pathologic variables, as well as improving pathologic differential diagnosis. Currently my investigations are centered on pathology of inherited ovarian and fallopian tube cancers.

I enjoy collaborative investigations not only with clinical colleagues but also with basic scientists and currently provide diagnostic services for a variety of scientists at UCSF in the area of women's cancers.

Education

Harvard Medical School, MD, 1992-98, Medicine
Harvard School of Public Health, M.P.H., 1995-96, Medicine
University of California, San Francisco, Intern, 1998-99, General Surgery
University of California, San Francisco Resident, 1999-01, Anatomic Pathology
University of California, San Francisco Fellow, 2001-02, Surgical Pathology
University of California, San Francisco, Fellow, 2002-03, Cytopathology
Harvard Medical School Fellow, 2003-04, Gynecologic and Breast Pathology


Professional Experience

  • 2001-02
    Chief Resident, Anatomic Pathology, University of California, San Francisco
  • 2003-04
    Clinical Fellow in Pathology, Harvard Medical School
  • 2003-04
    Fellow in Pathology of Women's Cancer, Gillette Center for Women's Cancer, Massachusetts General Hospital
  • 2003-04
    Graduate Assistant in Pathology, Massachusetts General Hospital
  • 2004-present
    Deputy Director, Medical Student Pathology Elective, University of California, San Francisco
  • 2004-present
    Associate Director, Surgical Pathology Fellowship, University of California, San Francisco
  • 2004-2008
    Assistant Professor in Clinical Pathology, University of California, San Francisco
  • 2008-present
    Associate Professor in Clinical Pathology, University of California, San Francisco

Selected Publications

  1. Winkelman WD, Rabban JT, Korn AP. Vaginal Calculus in a Woman With Mixed Urinary Incontinence and Vaginal Mesh Exposure. Female Pelvic Med Reconstr Surg. 2016 Mar-Apr; 22(2):e20-1.
    View on PubMed
  2. Moh M, Krings G, Ates D, Aysal A, Kim GE, Rabban JT. SATB2 Expression Distinguishes Ovarian Metastases of Colorectal and Appendiceal Origin From Primary Ovarian Tumors of Mucinous or Endometrioid Type. Am J Surg Pathol. 2016 Mar; 40(3):419-32.
    View on PubMed
  3. Karnezis AN, Wang Y, Ramos P, Hendricks WP, Oliva E, D'Angelo E, Prat J, Nucci MR, Nielsen TO, Chow C, Leung S, Kommoss F, Kommoss S, Silva A, Ronnett BM, Rabban JT, Bowtell DD, Weissman BE, Trent JM, Gilks CB, Huntsman DG. Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type. J Pathol. 2016 Feb; 238(3):389-400.
    View on PubMed
  4. Joseph NM, Solomon DA, Frizzell N, Rabban JT, Zaloudek C, Garg K. Morphology and Immunohistochemistry for 2SC and FH Aid in Detection of Fumarate Hydratase Gene Aberrations in Uterine Leiomyomas From Young Patients. Am J Surg Pathol. 2015 Nov; 39(11):1529-39.
    View on PubMed
  5. Rabban JT, Firetag B, Sangoi AR, Post MD, Zaloudek CJ. Incidental Pelvic and Para-aortic Lymph Node Lymphangioleiomyomatosis Detected During Surgical Staging of Pelvic Cancer in Women Without Symptomatic Pulmonary Lymphangioleiomyomatosis or Tuberous Sclerosis Complex. Am J Surg Pathol. 2015 Aug; 39(8):1015-25.
    View on PubMed
  6. Rabban JT, Vohra P, Zaloudek CJ. Nongynecologic Metastases to Fallopian Tube Mucosa: A Potential Mimic of Tubal High-grade Serous Carcinoma and Benign Tubal Mucinous Metaplasia or Nonmucinous Hyperplasia. Am J Surg Pathol. 2015 Jan; 39(1):35-51.
    View on PubMed
  7. Tamaresis JS, Irwin JC, Goldfien GA, Rabban JT, Burney RO, Nezhat C, DePaolo LV, Giudice LC. Molecular classification of endometriosis and disease stage using high-dimensional genomic data. Endocrinology. 2014 Dec; 155(12):4986-99.
    View on PubMed
  8. Rabban JT, Calkins SM, Karnezis AN, Grenert JP, Blanco A, Crawford B, Chen LM. Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome. Am J Surg Pathol. 2014 Jun; 38(6):793-800.
    View on PubMed
  9. Rabban JT, Garg K, Crawford B, Chen LM, Zaloudek CJ. Early detection of high-grade tubal serous carcinoma in women at low risk for hereditary breast and ovarian cancer syndrome by systematic examination of fallopian tubes incidentally removed during benign surgery. Am J Surg Pathol. 2014 Jun; 38(6):729-42.
    View on PubMed
  10. Rabban JT, Zaloudek CJ. A practical approach to immunohistochemical diagnosis of ovarian germ cell tumours and sex cord-stromal tumours. Histopathology. 2013 Jan; 62(1):71-88.
    View on PubMed
  11. Karnezis AN, Aysal A, Zaloudek CJ, Rabban JT. Transitional cell-like morphology in ovarian endometrioid carcinoma: morphologic, immunohistochemical, and behavioral features distinguishing it from high-grade serous carcinoma. Am J Surg Pathol. 2013 Jan; 37(1):24-37.
    View on PubMed
  12. Fadare O, Parkash V, Dupont WD, Acs G, Atkins KA, Irving JA, Pirog EC, Quade BJ, Quddus MR, Rabban JT, Vang R, Hecht JL. The diagnosis of endometrial carcinomas with clear cells by gynecologic pathologists: an assessment of interobserver variability and associated morphologic features. Am J Surg Pathol. 2012 Aug; 36(8):1107-18.
    View on PubMed
  13. Aysal A, Karnezis A, Medhi I, Grenert JP, Zaloudek CJ, Rabban JT. Ovarian endometrioid adenocarcinoma: incidence and clinical significance of the morphologic and immunohistochemical markers of mismatch repair protein defects and tumor microsatellite instability. Am J Surg Pathol. 2012 Feb; 36(2):163-72.
    View on PubMed
  14. Powell CB, Chen LM, McLennan J, Crawford B, Zaloudek C, Rabban JT, Moore DH, Ziegler J. Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol. Int J Gynecol Cancer. 2011 Jul; 21(5):846-51.
    View on PubMed
  15. Rabban JT, Mackey A, Powell CB, Crawford B, Zaloudek CJ, Chen LM. Correlation of macroscopic and microscopic pathology in risk reducing salpingo-oophorectomy: implications for intraoperative specimen evaluation. Gynecol Oncol. 2011 Jun 1; 121(3):466-71.
    View on PubMed
  16. Rabban JT, Karnezis AN, Zaloudek CJ. Junctional epithelial zones of the fallopian tube: cancer hotspots? Int J Gynecol Pathol. 2011 Jan; 30(1):1-3.
    View on PubMed
  17. Rabban JT, McAlhany S, Lerwill MF, Grenert JP, Zaloudek CJ. PAX2 distinguishes benign mesonephric and mullerian glandular lesions of the cervix from endocervical adenocarcinoma, including minimal deviation adenocarcinoma. Am J Surg Pathol. 2010 Feb; 34(2):137-46.
    View on PubMed
  18. Rabban JT, Krasik E, Chen LM, Powell CB, Crawford B, Zaloudek CJ. Multistep level sections to detect occult fallopian tube carcinoma in risk-reducing salpingo-oophorectomies from women with BRCA mutations: implications for defining an optimal specimen dissection protocol. Am J Surg Pathol. 2009 Dec; 33(12):1878-85.
    View on PubMed
  19. Rabban JT, Barnes M, Chen LM, Powell CB, Crawford B, Zaloudek CJ. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma. Am J Surg Pathol. 2009 Aug; 33(8):1125-36.
    View on PubMed
  20. Rabban JT, Glidden D, Kwan ML, Chen YY. Pure and predominantly pure intralymphatic breast carcinoma after neoadjuvant chemotherapy: an unusual and adverse pattern of residual disease. Am J Surg Pathol. 2009 Feb; 33(2):256-63.
    View on PubMed

Go to UCSF Profiles, powered by CTSI